BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19185917)

  • 1. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
    Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
    Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is survival enough for myelodysplastic syndromes?
    Santini V
    Leuk Res; 2009 Aug; 33(8):1017-8. PubMed ID: 19268362
    [No Abstract]   [Full Text] [Related]  

  • 3. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
    Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
    Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
    De Roos AJ; Deeg HJ; Davis S
    Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes.
    Candoni A; Raza A; Silvestri F; Lisak L; Galili N; Mumtaz M; Kikic F; Fanin R
    Ann Hematol; 2005 Jul; 84(7):479-81. PubMed ID: 15800786
    [No Abstract]   [Full Text] [Related]  

  • 7. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
    Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
    Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable response to antithymocyte globulin therapy in resistant acute graft-versus-host disease.
    Tagliabue A; Corti P; Viganò E; Bonanomi S; Uderzo C
    Bone Marrow Transplant; 2005 Sep; 36(5):459. PubMed ID: 15980883
    [No Abstract]   [Full Text] [Related]  

  • 11. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
    Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.
    Valera ET; Latorre Mdo R; Mendes WL; Seber A; Lee ML; de Paula MJ; Loggetto SR; Velloso E; Niero-Melo L; Lopes LF;
    Leuk Res; 2004 Sep; 28(9):933-9. PubMed ID: 15234570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with higher risk myelodysplastic syndromes.
    Fukumoto JS; Greenberg PL
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplasia: when to treat and how.
    Larson RA
    Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
    Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
    Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens.
    Leleu X; Terriou L; Duhamel A; Moreau AS; Andrieux J; Dupire S; Coiteux V; Berthon C; Micol JB; Guieze R; Facon T; Bauters F
    Ann Hematol; 2006 Oct; 85(10):711-6. PubMed ID: 16830141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunosuppressive treatment of the myelodysplastic syndrome].
    Larsen MS; Hasselbalch HC
    Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we nearer to curing patients with MDS?
    Sekeres MA
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):481-7. PubMed ID: 21130411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.